Oryzon names Greg Weaver CFO
This article was originally published in Scrip
Executive Summary
Oryzon Genomics, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases, has appointed Gregory L Weaver as executive vice-president and chief financial officer – effective 12 January 2015. Mr Weaver has served as CFO of several public biotech companies in the US, most recently Fibrocell Science. At Oryzon, he will report directly to Carlos Buesa, president and CEO of Oryzon, and will be based at the firm's US headquarters located in Cambridge, Massachusetts.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.